Depreciation, Depletion and Amortization of Revance Therapeutics, Inc. from 31 Mar 2019 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
Revance Therapeutics, Inc. quarterly and annual Depreciation, Depletion and Amortization in USD history and change rate from 31 Mar 2019 to 31 Mar 2024.
  • Revance Therapeutics, Inc. Depreciation, Depletion and Amortization for the quarter ending 31 Mar 2024 was $1,981,000, a 54% decline year-over-year.
  • Revance Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2023 was $11,375,000, a 66% decline from 2022.
  • Revance Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2022 was $33,732,000, a 70% increase from 2021.
  • Revance Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2021 was $19,853,000, a 94% increase from 2020.
Source SEC data
View on sec.gov
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Change (%)
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Change (%)

Revance Therapeutics, Inc. Quarterly Depreciation, Depletion and Amortization (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $1,981,000 -$2,320,000 -54% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q1 2023 $4,301,000 -$1,075,000 -20% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $5,376,000 +$1,135,000 +27% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q1 2021 $4,241,000 +$3,502,000 +474% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q1 2020 $739,000 +$111,000 +18% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q1 2019 $628,000 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1

Revance Therapeutics, Inc. Annual Depreciation, Depletion and Amortization (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $11,375,000 -$22,357,000 -66% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 $33,732,000 +$13,879,000 +70% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 $19,853,000 +$9,603,000 +94% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $10,250,000 +$7,341,000 +252% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $2,909,000 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.